Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verona Pharma PLC VRNA

Healthcare
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual... see more

Recent & Breaking News (NDAQ:VRNA)

Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018

GlobeNewswire May 8, 2018

Verona Pharma to Present at Bio€quity Europe 2018

GlobeNewswire May 4, 2018

Verona Pharma plc : Result of AGM

Hugin May 3, 2018

Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018

GlobeNewswire May 2, 2018

Verona Pharma Announces Departure of Chief Medical Officer

GlobeNewswire April 11, 2018

Verona Pharma plc : Total voting rights

Hugin October 2, 2017

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

GlobeNewswire September 27, 2017

Verona Pharma plc : Miscellaneous

Hugin September 19, 2017

Mid-Afternoon Market Update: NCI Building Drops On Downbeat Results; GoPro Shares Spike Higher

Benzinga.com  September 7, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 7, 2017

Mid-Day Market Update: RH Surges After Strong Results; Barnes & Noble Shares Slide

Benzinga.com  September 7, 2017

Mid-Morning Market Update: Markets Edge Lower; Conn's Profit Beats Views

Benzinga.com  September 7, 2017

Arix Bioscience plc notes positive trial data from Verona Pharma in COPD

GlobeNewswire September 7, 2017

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

GlobeNewswire September 7, 2017

Verona Pharma Appoints Stifel as Nominated Adviser

Hugin September 1, 2017

PDMR Dealing

GlobeNewswire August 21, 2017

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

Hugin August 8, 2017

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

GlobeNewswire August 8, 2017

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

GlobeNewswire August 2, 2017

Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 1, 2017